About Zymeworks inc.
Zymeworks Inc. is a clinical-stage biopharmaceutical company that is publicly listed on the New York Stock Exchange (NYSE: ZYME). The company is dedicated to discovering, developing, and commercializing next-generation multifunctional biotherapeutics with a primary focus on treating cancer.
The team at Zymeworks Inc. has developed a unique approach to drug discovery that involves the use of proprietary protein engineering technologies. These technologies allow for the creation of novel biotherapeutics that have multiple mechanisms of action, which can improve efficacy and reduce side effects.
One of the key advantages of Zymeworks' approach is its ability to create bispecific antibodies. Bispecific antibodies are designed to bind two different targets simultaneously, which can be particularly useful in cancer treatment where multiple pathways may need to be targeted for optimal efficacy.
Zymeworks' lead product candidate, ZW25, is a bispecific antibody that targets two different epitopes on HER2-positive cancer cells. HER2-positive cancers are known to be particularly aggressive and difficult to treat with traditional therapies. In preclinical studies, ZW25 has demonstrated potent anti-tumor activity against HER2-positive cancers while sparing healthy tissues.
In addition to its work on bispecific antibodies, Zymeworks also has several other programs in development focused on creating multifunctional biotherapeutics for the treatment of cancer and other diseases.
The company's commitment to innovation and excellence has earned it numerous awards and accolades over the years. In 2019 alone, Zymeworks was named one of Deloitte's Technology Fast 50™ Companies-to-Watch in Canada as well as one of BC's Top Employers by Mediacorp Canada Inc.
Zymeworks' success can also be attributed in part to its strong partnerships with leading pharmaceutical companies such as Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline plc (GSK), Daiichi Sankyo Company Limited (Daiichi Sankyo), Janssen Biotech Inc., Celgene Corporation (Celgene), BeiGene Ltd., Gilead Sciences Inc., Bausch Health Companies Inc., Mitsubishi Tanabe Pharma Corporation (MTPC), Servier Pharmaceuticals LLC (Servier) among others
Overall,Zymeworks inc.'s innovative approach towards drug discovery coupled with their dedication towards finding effective treatments for cancer makes them an industry leader in biopharmaceutical research today!